Obagi Medical Introduces NU-GEN™ Cellular Renewal Serum Designed to Visibly Rewind Skin’s Age and Restore Visible Youthfulness
Waldencast plc - Class A Ordinary Share (WALD)
Company Research
Source: GlobeNewswire
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), is proud to announce the latest innovation in advanced skin science and longevity with the launch of its newest breakthrough: Obagi NU-GEN™ Cellular Renewal Serum. A cellular renewal serum that acts like a power supply for your skin and supports its natural cellular functions. The formula is clinically proven to visibly rewind skin’s age by up to six years1 by helping replenish skin cells with NAD+ and addressing nine signs of skin aging simultaneously. At the core of the formula is Obagi’s proprietary AGE CTRL™ Complex, a scientifically advanced blend that delivers NAD+ along with its essential precursors, NMN and Niacinamide. This synergistic complex targets the leading cause of skin aging, supporting the skin’s longevity pathways – addressing visible sk
Show less
Read more
Impact Snapshot
Event Time:
WALD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WALD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WALD alerts
High impacting Waldencast plc - Class A Ordinary Share news events
Weekly update
A roundup of the hottest topics
WALD
News
- Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™GlobeNewswire
- Waldencast (WALD) had its price target lowered by Telsey Advisory Group from $3.00 to $2.00. They now have a "market perform" rating on the stock.MarketBeat
- Waldencast (WALD) had its price target lowered by Canaccord Genuity Group Inc. from $4.00 to $2.00. They now have a "buy" rating on the stock.MarketBeat
- Waldencast Reports Q4 2025 and FY 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Waldencast Reports Q4 2025 and FY 2025 Financial ResultsGlobeNewswire
WALD
Sec Filings
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- WALD's page on the SEC website